Transfusion-associated iron overload

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 436-441

  Hollán, Susan R ^a,b,c  

^a National Institute of Haematology and Immunology Budapest   (Hungary)

^b Natl Institute of Blood Transfusion ^*  (Hungary)

^c Natl Institute of Blood Transfusion   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; FREE RADICAL; IRON; TRANSFERRIN;

ALCOHOLISM; ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTAPHERESIS; ERYTHROCYTE CONCENTRATE; GENETIC SCREENING; HEMOCHROMATOSIS; HEPATITIS; HISTOCHEMISTRY; HLA MATCHING; HUMAN; HYPERCOAGULABILITY; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LIVER BIOPSY; MAGNETISM; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PERCEPTION DEAFNESS; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; REFRACTORY ANEMIA; RETINA INJURY; SHORT SURVEY; SIDE EFFECT; SPLENECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA; TRANSFERRIN BLOOD LEVEL;

EID: 0030862189     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00014     Document Type: Short Survey

References (54)

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 1996, 13:399-406. The first report on the identification of a most probable candidate gene (the missense mutation resulting in 282 Cys→Tyr substitution) in 87% of hereditary hemochromatosis patients. This enables screening for a common but widely underdiagnosed disease for which there is effective available therapy.
2. Halliwell B, Gutteridge JMC: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984, 219:1-14.
3. Slater TF: Free radical mechanisms in tissue injury. Biochem J 1984, 222:1-15.
4. Davies SC: Blood transfusion in sickle cell disease. Curr Opin Haematol 1996, 3:485-491. A concise survey with useful practical information on objectives, indications, and adverse effects of erythrocyte transfusion in sickle cell disease.
5. McKay PJ, Murphy JA, Cameron S, Burnett AK, Campbell M, Tausey P, Franklin IN: Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996, 17:63.
6. Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Manna M, Nesci S, et al.: Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996, 87:2082-2088. A thorough report on the transplantation outcome for 215 thalassemic patients with extensive liver damage (class 3 patients). It is concluded that patients with thalassemia who have HLA-identical family members should undergo transplantation before they are in class 3.
7. Harrison P, Neilson JR, Marwan SS, Madden L, Bareford D, Milligan DW: Role of non-transferrin bound iron in iron overload and liver dysfunction in long-term survivors of acute leukemia and bone marrow transplantation. J Clin Pathol 1996, 49:853-856.
8. Brittenham GM, Olivieri NF, Rouault TA: Iron physiology and iron overload. Hematology 1996, Educational Booklet of the American Society of Hematology. Dec. 7-8, Orlando, Florida, pp 177-186. An excellent summary of recent advances in iron physiology, including molecular regulation of cellular iron uptake and storage and techniques for the evaluation of ron status in iron overload. New findings in screening, diagnosis, and treatment of hereditary hemochromatosis and transfusional overload are surveyed.
9. Rubin RB, Barton AL, Banner BF, Bonkovsky HL: Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 1995, 13:223-238.
10. Piperno AD, Alba R, Fergion S, Roffi L, Sampietro M, Parma S, Arosio V, Fare M, Fiorelli G: Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur J Gastroenterol Hepatol 1995, 7:1203-1208.
11. Hasan MF, Marsh F, Posner G, Bellevue R, Dosik H, Suatengo R, Romani N: Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol 1996, 91:1204-1206.
12. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al.: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent Science 1996, 271:505-508. The first report on the cloning and sequencing of the entire hepatitis G virus (HGV) genome. HGV was found to be closely related to GB virus C (GBV-C) and distantly related to HCV, GBV-A and GBV-B. HGV was shown to be associated with acute and chronic hepatitis and to be transfusion-transmissible. It is globally distributed and is present within the volunteer blood donor population in the United States. Screening of 779 volunteer donors with normal alanine amino-transferase (ALT) values revealed HGV-RNA positivity in 1.7%, as determined by polymerase chain reaction and 1.5% RNA positivity among 705 donors excluded from donation because of an elevated ALT level.
13. Sorvajarvi K, Blake JB, Israel Y, Wiemala O: Sensitivity and specificity of carbohydrate deficient transferrin as marker of alcohol abuse are significantly influenced by alterations in serum transferrin: comparison of two methods. Alcohol Clin Exp Res (US) 1996, 20:449-454.
14. Ohnuma K, Toyoda Y, Nishihira H, Iguchi A, Tabuchi K, Honda K, Nagao T, Kigashawa H, Ivahori A: Detection of early cardiac dysfunction in patients with transfusion-dependent aplastic anemia and chronic iron overload in childhood. Rinsho Ketsueki 1996, 37:825-832.
15. Pepper JR, Mumby S, Gutteridge JM: Blood cardioplegia increases plasma iron overload and thiol levels during cardiopulmonary bypass. Ann Thorac Surg 1995, 60:1735-1740.
16. Tai DY, Wang YT, Lou J, Wang WY, Mak KH, Cheng HK: Lungs in thalassaemia major patients receiving regular transfusion. Europ Respir J 1996, 9:1388-1894.
17. Soliman AT, Banna N, al Salmi I, Asfour M: Insulin and glucagon responses to provocation with glucose and arginine in prepubertal children with thalassaemia major and after long-term blood transfusion. J Trop Pediatr 1996, 42:291-296.
18. Hollán S, Staehr-Johansen K: Adequate iron stores and the 'Nil nocere principle'. Haematologia 1993, 25:69-84. A comprehensive review on cellular iron metabolism and on the adverse effects of non-transferrin-bound iron on infection and malignancy and on the risks of indiscriminate iron medication.
19. Kontoghiorghes GJ, Weinberg ED: Iron: Mammalian defence systems, mechanism of disease, and chelation therapy approaches. Blood Reviews 1995, 9:33-45. This paper gives a broad overview on the role of iron in mammalian defense systems and the mechanism of iron-induced tissue damage in different diseases. Trials of approaches to the use of chelation as an adjunct therapy are also reported.
20. Ljungberg P, Valtonen M, Harjola VP, Kaukoranta-Tolvanen SS, Vaara M: Report of four cases of Yersinia pseudotuberculosis septicaemia and a literature review. Eur J Clin Microbiol Infect Dis 1995, 14:804-810.
21. Cardier J, Romano E, Soyano A: Effect of hepatic isoferritins from iron overloaded rats on lymphocyte proliferative response: role of ferritin iron content Immunopharmacol Immunotoxicol 1996, 17:719-732.
22. Fimmel CJ, Brown KB, O'Neill R, Kladney RD: Complement C4 protein expression by rat hepatic stellate cells. J Immunol 1996, 157:2601-2609.
23. Carrasco-Marin E, Alvarez-Dominguez C, Lopez-Mato P, Martinez-Palencia R, Leyva-Cobian F: Iron salts and iron-containing porphyrins block presentation of protein antigens by macrophages to MHC class II-restricted T cells. Cell Immunol (USA) 1996, 171:173-185.
24. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassaemia. Blood 1997, 89:738-761. An excellent review article on the recent state of the art of the assessment, prevention, and treatment of iron overload. Gives comprehensive practical advice on how to treat thalassemic patients. It summarizes effectiveness and toxicity of deferioxamine and deferiprone.
25. Girelli D, Corrocher R, Bisceglia L, Olivieri O, de Francheschi L, Gasparini P: Molecular basis for the recently described 'hereditary hyperferritinemia-cataract syndrome'. A mutation in the iron responsive element of ferritin L-subunit gene (the 'Verona-mutation'). Blood 1995, 86:4050-4086.
26. Gungor T, Rohrbach E, Solem E, Kaltwasser JP, Komhuber B: Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis. Arch Dis Child 1996, 74:323-327.
27. Nielsen P, Fischer R, Engelhardt R, Tondüry P, Gabbe EE, Janka GE: Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine and deferiprone. Brit J Haematol 1995, 91:827-833.
28. Liu P, Henkelman M, Joshi J, Hardy P, Butany J, Iwanochko M, Claudberg M, Dhar M, Mai D, Waien S, Olivieri NF: Quantitation of cardiac and tissue iron by nuclear magnetic resonance In a novel murine thalassemia-cardiac-iron overload model. Can J Cardiol 1996, 12:155-164.
29. Levin TL, Seth SS, Hurlet A, Comerci SC, Ruzal-Shapiro C, Piomelli S, Berdon WE: MR marrow signs of iron overload in transfusion-dependent patients with sickle cell disease. Pediatr Radiol 1995, 25:614-619.
30. Mazza P, Gina R, De Marco S, Bonetti MG, Amurri B, Masi C, Lazzari G, Rizzo C, Carvellera M, Peluso A, et al.: Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica 1995, 80:398-404.
31. Kelekis NL, Semelka RC, Jeon HJ, Sallah AS, Shea TC, Woosley JT: Dark ring sign: Finding in patients with fungal liver lesions and transfusional hemosiderosis undergoing treatment with antifungal antibodies. J Magn Reson Imaging 1996, 14:615-618.
32. Emy PY, Levin TL, Seth SS, Ruzalshapiro C, Garvin J, Berdon WE: Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. Am J Roentgenol 1997, 168:1011-1015.
33. Celckers S, Graeff W: In situ measurement of iron overload in liver tissue by dual-energy methods. Phys Med Biol 1996, 41:1149-1165.
34. Bonetti MG, Castriota-Scanderbeg A, Criconia GM, Mazza P, Sacco M, Amurri B, Masi C: Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment Pediatr Radiol 1996, 26:650-656.
35. Papaconstantinon OG, Maris TG, Kostaridon V, Gouliamos AD, Koutoulas GK, Kalovidouris AE, Papavassiliou GB, Kordas G, Kattamis C, Vlahos LJ, et al.: Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging 1995, 13:967-977.
36. Collins AF, Dias GC, Haddad S, Talbot R, Herst R, Tyler BJ, Zuber E, Blanchette VS, Olivieri NF: Evaluation of a new neocyte transfusion preparation vs. washed cell transfusion in patients with homozygous beta thalassaemia. Transfusion 1994, 34:517-520.
37. Gavoni M, Lodi GL, Lughi M: Red cell exchange transfusion in severe HbS/β thalassaemia double heterozygotes. Vox Sang 1995, 68:248.
38. Adams DM, Schultz WH, Ware RE, Kinney TR: Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Oncol 1996, 18:46-50.
39. Lumadue JA, Ness PM: Current approaches to red cell transfusion. Semin Haematol 1996, 88:277-289. A good and timely summary of the misuse of red blood cell transfusion originating from the concept of a "transfusion trigger" developed in the era before the heightened awareness of transfusion-transmitted diseases. Recent practice in red blood cell preservation, storage, and transfusion practices in different fields of indication are being discussed with special emphasis on iron overload and red blood cell alloimmunization.
40. Hollán S: Iron supplementation and cognitive function [letter]. Lancet 1996, 348:1669-1670. This letter addresses the additional dangers of iron-induced free radical release to pregnant women who are in a physiologically hypercoagulable state and suggests consideration of the eventual long-term oncogenic effects of free iron to the highly proliferative tissues of the fetus, especially in the presence of viral infections.
41. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Haematol 1995, 32:304-312.
42. Porter JB, Abeysinghe RD, Marshall R, Hider RC, Singh S: Kinetics of removal and reappearance of non-transferrin-bound plasma iron to chelation therapy. Blood 1996, 88:705-713. This study demonstrates the rapidity and duration of the response of non-transferrin-bound iron to chelation therapy by measuring simultaneously non-transferrin-bound iron, deferoxamine, and its major metabolite in thalassemia major patients on intravenous deferoxamine. The authors conclude that the marked lability of non-transferrin-bound iron supports the use of continuous rather than intermittent deferoxamine in high-risk patients.
43. Styles LA, Vichinsky EP: Ototoxicity in hemglobinopathy patients chelated with desferrioxamine. J Pediatr Haematol Oncol 1996, 18:43-45.
44. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C: Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996, 155:368-372.
45. Levin TL, Seth S, Berdon WE, Ruzal-Shapiro C, Piomelli S: Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients. Pediatr Radiol 1995, Suppl 1:122-124.
46. Gazlev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maielio A, Lucarelli G: Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995, 80:300-304.
47. Sokol RJ: Antioxidant defenses In metal-induced liver damage. Semin Liver Dis 1996, 16:39-46.
48. Araujo A, Kosaryan M, McDowell A, Wickens B, Puri S, Wonke B, Hoffbrand AV: A novel delivery system for continuous desferrioxamine infusion in transfusion iron overload. Brit J Haematol 1996, 93:835-837.
49. Paolo C, Francesco S, Sergio A: Management of iron overload with a disposable multi-day delvery system [letter]. Am J Hematol 1996, 51:95.
50. Olivieri NF, Berriman AM, Davis SA, Tyler BJ, Ingram J, Francombe WH: Continuous intravenous administration of deferoxamine in adults with severe iron overload. Am J Hematol 1992, 41:61-63.
51. Borgna-Pignatti C, Cohen AR: An alternative method of subcutaneous deferoxamine administration [abstract]. Blood 1995, 86(suppl 1):483a.
52. Singh S, Khodr H, Taylor MI, Hider RC: Therapeutic iron chelators and their potential side-effects. Biochem Soc Symp 1995, 61:127-137.
53. Hoffbrand AV: Oral iron chelation. Semin haematol 1996, 33:1-8. Pharmacology and the results of clinical studies of iron chelation therapy are summarized. Detailed report is given on the advantages and adverse effects of deferiprone.
54. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995, 332:918-922.